Best Healthcare Companies in China
The 1599 best Healthcare companies in China in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Wuhan Asian Heart Hospital.
China's Healthcare sector is bigger and more contested than most outsiders assume, and this directory tracks 1,599 companies to help you cut through the noise, ranked by disclosed equity funding and recent momentum. Total disclosed funding across the cohort sits at $16.8B, which tells you capital has been moving here at scale. VelaVigo leads individual raises at $160M, with BrightGene ($80M) and Excalipoint ($69M) not far behind, and active backers like Qiming Venture Partners, Legend Capital, and OrbiMed keep the deal flow steady. The global market crossed $2 trillion in 2020 and is forecast to reach roughly $2.6T by 2025 at a 6.3% CAGR, driven partly by shifting consumer preferences toward virtual and convenient care delivery. Strict product safety compliance remains the structural constraint every company here has to price in.
So what's actually moving right now? Vaccine-related themes, including candidates, trials, immunogenicity data, and active campaigns, are the clearest hot spots, even as broader coverage stays flat. App adoption is a real signal too: median install growth is running at roughly +16% YoY across 53 healthcare app categories tracked this quarter. Models built around managed care revenue retention are gaining structural traction as payers tighten, and I'd watch that trend closely alongside vaccine pipeline activity. The 1,599 companies here span that full range.
- Global Healthcare to Soar Above $2 Trillion in 2020 with Consumerism a
- Healthcare Consumers in Asia-Pacific Prefer a Single Touchpoint
Ranked: Best Healthcare companies in China
| # | Company | Disclosed funding | Last round | Stage | Employees | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Wuhan Asian Heart Hospital Provider of mobile phone, gadget, and travel insurance policies | $550M | 52 mo ago | Series D | 116 | 2002 | SwiperjQuery UIjQuery+2 | — | — |
| 2 | Huadong Medicine Manufacturer of pharmaceutical products | $532M | 124 mo ago | Public | 14,061 | 1993 | — | 17 patents Oral anti-diabetic drugs and formulations, including acarbose and combination therapies | — |
| 3 | Haoyisheng Provider of medical data management, channel communication, and marketing services for hospitals | $500M | 120 mo ago | Series A | — | 1999 | JavaNginxjQuery | — | — |
| 4 | MediTrust Health Provider of medical payment services | $463M | 41 mo ago | Series C | 132 | 2017 | — | — | — |
| 5 | CStone Pharma Developing and licensing novel drugs for diseases including cancer and autoimmune diseases | $410M | 68 mo ago | Public | 476 | 2016 | — | — | 1 partnership |
| 6 | Ausco Biopharma Developer of recombinant proteins | $407M | 53 mo ago | Series D | — | 2017 | — | — | — |
| 7 | FITURE Standalone fitness center | $391M | 62 mo ago | Series B | 1,200 | 2019 | SentryZendeskNode.js+27 | — | — |
| 8 | Pharmaron Suite of drug discovery and development services for small molecules | $320M | 126 mo ago | Public | 476 | 2003 | WordPress Block EditorWordPressMySQL+23 | — | — |
| 9 | Chime Biologics Provider of contract development and manufacturing services catering to the biopharma sector | $315M | 62 mo ago | Series A | 400 | 2013 | WordPressMySQLPHP+15 | — | 1 partnership |
| 10 | Chemclin Provider of in vitro diagnostics instruments and auxiliary reagents | $313M | 94 mo ago | Acquired | 658 | 2007 | — | — | — |
| 11 | Mabwell R & D company focused on manufacturing of pharmaceutical products for multiple therapeutic products | $278M | 73 mo ago | Public | 1,451 | 2017 | PHPUbuntuApache HTTP Server+3 | — | — |
| 12 | Abbisko Therapeutics Developing novel small molecule drugs for immunomodulatory pathways to treat cancer | $263M | 65 mo ago | Public | 252 | 2016 | — | 309 patents Small-molecule kinase inhibitor drugs targeting FGFR4, CSF‑1R, CDK, CD73, PARP for cancer therapy | — |
| 13 | ZGBiotech CDMO focused on drug development, analytical, formulation, and quality testing services 72Funding top 24%Market top 28%Global bottom 38% All 3 signals ▾Fundingtop 24% Markettop 28% Globalbottom 38% Funding: Raised $240M across 4 rounds · 4 rounds over 6 yrs (0.7/yr) Market: 600 employees (top 9% of Industrial Goods and Manufacturing) rank vs industry peers · Fliar Intelligence Index 72/100 | $240M | 46 mo ago | Series C | 600 | 2017 | — | — | — |
| 14 | Shandong Xuanzhu Pharmaceutical Technology Developer of therapies for treating cardiovascular diseases, cancer, and diabetes | $210M | 53 mo ago | Series B | — | 2002 | — | — | — |
| 15 | Shanghai Cell Therapy Group Provider of cell-therapy focused research and development services | $202M | 62 mo ago | Series D | 70 | 2014 | PHPLayuiTengine+3 | — | — |
| 16 | Viva Biotech Research services focused on drug discovery and development | $180M | 36 mo ago | Public | 2,271 | 2006 | PHPNginxSwiper+7 | — | — |
| 17 | Innoforce Pharmaceuticals Manufacturer of biopharmaceuticals | $179M | 54 mo ago | Series A | 2 | 2018 | — | — | — |
| 18 | DistinctClinic Chain of general clinics | $168M | 57 mo ago | Public | 36 | 2012 | Node.jsKongNginx+4 | — | 2 partnerships · 2 expansions |
| 19 | Jilin Huisheng Bio-Pharmaceutical Provider of drug research, clinical development, marketing, and other services | $160M | 41 mo ago | Series A | 200 | 2019 | — | — | — |
| 20 | VelaVigo Biotechnology research company developing biological drugs | $160M | 10 mo ago | Seed | — | 2021 | — | — | 1 job opening |
| 21 | Virtue Diagnostics Provider of an in vitro assay platform for diagnostic solutions | $130M | 53 mo ago | Series B | 500 | 2019 | — | — | 1 job opening |
| 22 | Jiangsu Vcare Pharmatech CDMO manufacturing APIs | $107M | 29 mo ago | Series C | 500 | 2010 | — | 66 patents Small‑molecule kinase and receptor modulators for inflammatory and oncologic therapies | — |
| 23 | JJET R&D company focused on producing and supplying of medical devices | $103M | 45 mo ago | Series B | 321 | 1991 | — | — | — |
| 24 | Tongshu Biotechnology Research lab focused on gene sequencing technology and biological information analysis | $92M | 20 mo ago | Series D | 1 | 2016 | — | — | — |
| 25 | BrightGene Manufacturer of pharmaceutical formulations, active pharmaceutical ingredients, and veterinary drugs | $80M | 3 mo ago | Series C | 559 | 2001 | — | — | — |
| 26 | Porton Advanced Solutions Provider of cell & gene therapy, discovery research, analytical development, and testing services | $80M | 45 mo ago | Series B | — | 2018 | WordPressMySQLPHP+18 | — | 1 launch |
| 27 | lynkpharma.com Limited information available | $78M | 32 mo ago | Series C | 40 | 2017 | — | — | — |
| 28 | Readline R&D company manufacturing and exporting cosmetic, drug, and amino acid peptides | $74M | 15 mo ago | Series C | 300 | 2013 | jQuerySlickBaidu Analytics (百度统计) | — | — |
| 29 | Zhejiang Mingdu Zhikong Technology Provider of AI based logistics services | $73M | 27 mo ago | Series C | 500 | 2017 | — | — | — |
| 30 | Excalipoint Biotechnology company developing next-generation T-cell engager platforms for cancer and autoimmune diseases | $69M | 3 mo ago | Seed | — | 2025 | — | — | — |
| 31 | Methuselah Medical Technology Supplier and manufacturer of medical nutrition products | $41M | 10 mo ago | Series B | 68 | 2012 | — | — | — |
| 32 | Canton Biologics CDMO focused on manufacturing of cell based therapy products | $41M | 33 mo ago | Series C | 100 | 2016 | — | 17 patents Recombinant protein expression and bispecific antibody manufacturing technologies | — |
| 33 | Eccogene CRO focused on development of drugs for metabolic and immune-related diseases | $40M | 36 mo ago | Series B | — | 2018 | — | 3 patents SSAO enzyme inhibitors—heterocyclic small‑molecule pharmaceuticals targeting amine oxidase activity | — |
| 34 | Phase Scientific Provider of technology for diagnostics tools | $36M | 12 mo ago | Series A | 20 | 2012 | — | 6 patents Nucleic acid purification and size-selective enrichment kits for RNA/DNA analysis | — |
| 35 | SAINT BELLA Postpartum care brand offering maternity and baby care products | $31M | 34 mo ago | Public | — | 2017 | Animate.cssVue.jsjQuery+6 | — | — |
| 36 | CHIGENOVO Biotechnology company focused on developing gene therapy drugs for eye diseases | $26M | 32 mo ago | Series A | — | 2016 | — | 41 patents AAV‑based gene therapy and editing platforms for inherited retinal dystrophies | — |
| 37 | ChemLex Provider of consulting services in the field of chemical research and development through artificial… | $26M | 6 mo ago | Series B | — | — | BootstrapGSAPAmazon Web Services+5 | — | — |
| 38 | Rezubio Manufacturer of generic drugs | $20M | 5 mo ago | Series A | 5 | 2019 | — | — | — |
| 39 | Regend Therapeutics CDMO focused on manufacturing of cell & gene therapy services | $16M | 4 mo ago | Series C | — | 2015 | — | 10 patents Autologous cell‑based regenerative therapies for pulmonary fibrosis and kidney regeneration | — |
| 40 | Gffac Fitness centers chain | $15M | 24 mo ago | Series C | 1,000 | 2012 | — | — | — |
| 41 | Beijing Ruifen Biotechnology R&D company focused on manufacturing of plant functional ingredients | $14M | 5 mo ago | Series C | 200 | 2007 | — | — | — |
| 42 | ICE Bioscience Specialised CRO offering a range of screening platforms for cardiac safety testing, ion channel profiling and… | $14M | 25 mo ago | Series C | 19 | 2010 | anime.jsYouTubeNginx+7 | — | — |
| 43 | Bonabio | $14M | 22 mo ago | Series A | — | — | — | — | — |
| 44 | Blue Sail Surgery Provider of surgical instruments | $14M | 24 mo ago | Series A | 7,373 | 2020 | NginxSwiperSweetAlert+2 | — | — |
| 45 | Lead Biopharmaceuticals | $14M | 18 mo ago | Series A | — | 2019 | — | — | — |
| 46 | Yiyuan Provider of R&D, production, sales, technical, and consultation services for medical X-ray tubes | $14M | 4 mo ago | Series B | 80 | 2018 | — | 11 patents Patents concentrated in computing, sensing & instrumentation | — |
| 47 | Xinzeyuan Medical Technology Provider of medical accessories and medical device consumables | $14M | 16 mo ago | Series B | 300 | 2010 | — | — | — |
| 48 | FUSIONTECH Provider of hospital evaluation, medical record systems, and application development services | $7M | 7 mo ago | Seed | 150 | 2017 | — | — | — |
| 49 | Xinyun Medical Healthcare consortium offering consulting services to healthcare providers | $3M | 9 mo ago | Series B | 100 | 2016 | — | — | — |
| 50 | EnsiliTech CDMO focused on antibodies, vaccines, and other therapeutics drugs development services | $1M | 9 mo ago | Seed | 7 | 2022 | Cart FunctionalitySquarespace CommerceSquarespace+15 | — | 4 awards |
Top 12 Healthcare companies in China
#1
Series C · Suzhou, Jiangsu · founded 2001 · 559 employees$80Mraised▾
Manufacturer of pharmaceutical formulations, active pharmaceutical ingredients, and veterinary drugs. The company develops and produces a range of pharmaceutical products, including formulations for human use and active pharmaceutical ingredients. It also offers products related to veterinary medicine. A robust research and development system supports innovation and quality control throughout the production process. The company maintains comprehensive production and quality systems.
- Mar 2026Series C—
- Jan 2019Series C$80M
#2
Seed · Shanghai, Shanghai · founded 2025$68.7Mraised▾
Biotechnology company developing next-generation T-cell engager platforms for cancer and autoimmune diseases. The company aims to overcome tumor challenges in immunology and oncology.
- Mar 2026Seed$68.7M
#3
Seed · Shanghai, Shanghai · founded 2021$160Mraised▾
Biotechnology research company developing biological drugs. It is a biopharmaceutical research company that develops biological drugs including bispecific and multi specific antibodies, ADC, and new modalities.
- Jul 2025Seed$60M
- Dec 2024Seed$50M
- Nov 2021Angel$50M
#4
Series C · Suzhou, Jiangsu · founded 2015$15.8Mraised▾
Developer of stem cell therapy products and human organ regenerative medicine. The company is mainly engaged in research and development of regenerative medicine, providing users with interstitial lung disease, assisted reproduction, stem cell storage and chronic obstructive pulmonary disease treatment solutions.
- Feb 2026Series C$50.6M
- Mar 2022Series B$15.8M
#5
Series B · Suzhou, Jiangsu · founded 2018 · 80 employees$13.8Mraised▾
Provider of R&D, production, sales, technical, and consultation services for medical X-ray tubes
- Jan 2026Series A$14.4M
- Jul 2023Series B$13.8M
- Sep 2021Seed—
#6
Series B · Shanghai, Shanghai$26Mraised▾
ChemLex is a knowledge-based company that focuses on closed-loop collaborative research and development through artificial intelligence chemical synthesis path planning and high-throughput. They offer comprehensive consulting services in the field of chemical legislation and plant protection products.
- Dec 2025Series B$45M
#7
Series A · Zhuhai, Guangdong Province · founded 2019 · 5 employees$20Mraised▾
Manufacturer of generic drugs
- Dec 2025Series A$20M
- Feb 2023Seed—
#8
Series C · Haidian, Beijing · founded 2007 · 200 employees$14.2Mraised▾
R&D company focused on manufacturing of plant functional ingredients
- Dec 2025Series C$14.2M
- Oct 2021Series B—
- Apr 2021Series A—
#9
Series B · Shanghai, Shanghai · founded 2012 · 68 employees$41.4Mraised▾
Supplier and manufacturer of medical nutrition products
- Aug 2025Series B$13.9M
- Feb 2025Series B$27.5M
- Dec 2022Series A—
#10
Series A · Hong Kong, Hong Kong · founded 2012 · 20 employees$36Mraised▾
Phase Scientific provides the technology for diagnostics tools. It offers its propriety point-of-care test kits for infectious diseases, including tooth decay, hepatitis, malaria, and sexually transmitted diseases, liquid biopsy for an early stage of cancer determination, it also offers health data platform and mobile app connected to a database and analytical to manage health risks. It also offers animal health, food safety, and environmental testing.
- May 2025Series A$34M
- May 2017Grant (prize money)$749.8K
- Mar 2017Grant (prize money)$1.1M
- Jan 2016Grant (prize money)$150K
#11
Series C · Shenzhen, Guangdong Province · founded 2013 · 300 employees$74.3Mraised▾
R&D company manufacturing and exporting cosmetic, drug, and amino acid peptides
- Feb 2025Series C$68.9M
- Dec 2022Series B$43M
- Nov 2021Series A$31.3M
#12
Seed · Wuhan, Hubei · founded 2017 · 150 employees$7.3Mraised▾
Provider of hospital evaluation, medical record systems, and application development services
- Nov 2025Seed$7M
- Mar 2023Angel$7.3M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Healthcare coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.